References
- American Diabetes AssociationDiagnosis and classification of diabetes mellitusDiabetes Care201437Suppl 1S81S9024357215
- GarberAJAbrahamsonMJBarzilayJIAACE comprehensive diabetes management algorithm 2013Endocr Pract201319232733623598536
- InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care201538114014925538310
- DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet200636895481696170517098089
- RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915654055919858063
- KimTELimKSParkMKEvaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human studyClin Ther20123491986199822943970
- GuNParkMKKimTEMultiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteersDrug Des Devel Ther2014817091721
- JungCHParkCYAhnKJA randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exerciseDiabetes Metab Res Rev201531329530625362864
- BoultonDWSmithCHLiLHuangJTangALaCretaFPBioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjectsClin Drug Investig2011319619630
- BlondeLWogenJKreilickCSeymourAAGreater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metforminDiabetes Obes Metab20035642443114617228
- BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120871371917679131
- World Health OrganizationGuidelines for registration of fixed-dose combination medicinal productsWHO Technical Report Series2005 Available from: http://apps.who.int/prequal/info_general/documents/TRS929/WHO_TRS_929_annex5FDCs.pdfAccessed March 5, 2016
- National Institute of Toxicology ResearchGuideline on food-effect bioavailability and fed bioequivalence studiesMinistry of Food and Drug Safety (MFDS)2005 Available from: http://www.mfds.go.kr/index.do?mid=695&pageNo=81&seq=714&cmd=vAccessed March 5, 2016
- US Food and Drug AdministrationDrug label information: GLUCOPHAGE XRFDA2008 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdfAccessed March 5, 2016
- GrahamGGPuntJAroraMClinical pharmacokinetics of metforminClin Pharmacokinet2011502819821241070
- US Food and Drug AdministrationGuidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs – General ConsiderationsFDA2014 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdfAccessed March 5, 2016
- Committee for Medicinal Products for Human Use and European Medicines AgencyGuideline on the investigation of bioequivalenceEMA2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdfAccessed March 5, 2016